Source: Phileo by Lesaffre via Feedinfo News Service

18 July 2019 – Initially launched for the Asian and European markets at EuroTier in November last year, Phileo by Lesaffre’s Actisaf HR+ live yeast probiotic (Actisaf® Sc 47 HR+ new generation) has since been rolled out in the Americas and the response of the market has been unanimously good. The product is seen to have higher resistance to the rough handling of feed processing than its predecessors without any loss of efficacy – enabling the company to take what it describes as an “unrivalled step forward” within the live yeast probiotics market.

Gildas Joalland, Global Strategy Director, and Eric Auclair, Global R&D Director at Phileo by Lesaffre take us behind the scenes and explain why the above claim is not just a marketing stunt, but a statement made based on science, relentless testing, and company investment.

Gildas Joalland
Global Strategy Director
Phileo by Lesaffre

[Feedinfo News Service] In which ways is Actisaf HR+ new generation innovative?

[Gildas Joalland] Actisaf HR+ new generation is really an innovation responding to the need of the market. When used as an additive in feed, it helps stabilize the microflora balance and improve digestion for better performance and better delivery of quality end products. For probiotics to work in the gut they have to stay alive during the pelleting process. And that is exactly what Actisaf HR+ new generation does. This new product, still entirely made of pure yeast, is equipped with far higher pelleting resistance than the previous version. It is also designed to meet the considerable cost optimization demands which apply to all modern pelleting activities.

[Eric Auclair] Actisaf intrinsic resistance to multiple factors starts with the selection of the reference proprietary Sc47 strain among the yeast strains library of Lesaffre. This proprietary strain is combining proven benefits for the animal together with its robustness and resistance to challenging physico-chemical stress factors. It is powered by exclusive fermentation and drying process technologies to develop highly resistant yeast microspherulas. Each microspherula contains 40 million live yeast cells with no need for additional coating to allow faster release and activity after feed ingestion compared to classical coating technology.

[Feedinfo News Service] Lesaffre is known as a world leader in yeast production with an integrated approach and expertise. Yet despite the brand recognition Lesaffre Feed Additives became Phileo in 2015. Since the new name and rebranding, how would you measure the market success rate of the company’s feed yeast range?

[Gildas Joalland] Fermentation, is our history, but also our future! Whether in bread-making or in the fields of taste & food pleasure, well-being & health or biotechnology, Lesaffre has been relying for many years on its fermentation expertise to develop innovative solutions for its customers. And at Phileo by Lesaffre we are relying on that expertise every day. Our scientists work in close co-operation with their colleagues at our research facilities, like the newly opened “In Vitro Platform.”

This platform enables us to validate the effectiveness of our existing and future products, develop new solutions and thus strengthen even more our scientific and technical know-how. Located in the Eurasanté Park close to Lille (Loos, France), the platform is perfectly aligned with Lesaffre’s commitment to highlight the full potential of microorganisms and fermentation for the nutrition and health of tomorrow. It completes three Lesaffre research platforms already present in the Eurasanté Park: one platform dedicated to bacteria, another on enzymes and the third one to purification and molecules extraction. To equip the in vitro platform with modern technology, Lesaffre signed a partnership with the Dutch company, Triskelion. The core of the collaboration the so-called TIM-1 system, is a dynamic in vitro model of the stomach and small intestine developed by Triskelion. With this innovative system, capable of mimicking gastrointestinal processes, our teams have now the opportunity to study the ability of our products to survive and be active in the intestine of animals or to improve nutrient digestibility. In the context of antibiotic reduction worldwide, Phileo now benefits from Lesaffre expertise not only in yeast but also in sporulated and non-sporulated bacteria and future development with bacteriophages technologies.

Eric Auclair
Global R&D Director
Phileo by Lesaffre

[Feedinfo News Service] Did you see discrepancies between pilot and industrial level tests? How complex can yeast survival be?

[Eric Auclair] Rigorously tested at pilot level (across no fewer than 125 pilot trials) before being unveiled at EuroTier, Actisaf® Sc 47 HR+ new generation has followed its public launch by being exposed to six months of stringent scientific and practical examination under full commercial conditions. This included being part of industrial trials carried out at 13 different pelleting locations in Europe and Russia and 4 in Asia. 53% of the trials focused on swine feed, where pelleting parameters are routinely at their most challenging. Ruminant feed pelleting, meanwhile, accounted for 35% of the trials with the remaining 12% being used to cover all other feeds, including horse products. Multi-sampling of feed products was taken at different points of the pelleting process with all technological parameters being rigorously recorded at each key point of the pelleting chain. Pelleting demands ranged from ‘severe’ to ‘extreme’ with 14 of the trials using a simple pelletizer and 3 using a double pelletizer. A standard conditioner was used for the 3 double pelletizer trials and 11 of the simple pelletizer trials. The remaining 3 simple pelletizer trials used a BOA compactor process. Because adding moisture and temperature via steam during the conditioning step may have adverse effects on active ingredients, the Specific Thermal Energy (STE) of each process was also recorded. The 17-trial conclusion was that Actisaf® Sc 47 HR+ new generation is equipped with top-level resistance, enabling it to embrace the demands of modern pelleting, under a large variety of trial conditions, with a high degree of consistency and conformity and with CFU counts grouped between 6.3 and 7 log CFU/g.

[Feedinfo News Service] Phileo by Lesaffre likes to promote the diversity of its Actisaf range and its global network of feed technology experts. What does this say about your approach to the multitude of global nutritional challenges?

[Gildas Joalland] The need to keep up with the latest technical requirements of modern feed processing (such as the use of far higher heat treatments but also compression-friction forces and humidity than were used in the past) led to last year’s launch of Actisaf® Sc 47 HR+ new generation. The company’s original solution, launched ten years ago, was Actisaf® Sc 47 HR+, a concentrate of live yeast Saccharomyces cerevisiae Sc 47 processed into a micro spherule form, enabling it to remain alive and fully active under the pelleting conditions that existed at the time. But it is all about continuous innovation, as our industry is under continuous evolution. This also takes form via the support of a large network of feed technology experts over the world, long-term partnerships including identification of the key-technological parameters related to yeast survival, but also pilot trials and training for customers (Zetadec, Tecaliman, Feed Design Lab, Kennesaw State University, North Carolina State University, MAFIC…)

[Feedinfo News Service] Phileo by Lesaffre’s Feed tech Service was launched at the same time as Actisaf® Sc 47 HR+ new generation. What is this service?

[Eric Auclair] The new Feed tech Service is a complementary initiative to better support feed manufacturers’ specific needs. The service offers the three main pillars of technical assistance, information sharing and in-depth training to better serve Phileo by Lesaffre’s customers. Offering technical feed service to customers is close to our heart trying to help them overcome new and emerging challenges. Our knowledge has increased over the past ten years, enabling us to now give customers a clearer view of the resistance of probiotics to the multifactorial challenges which occur in feed during pelleting. Meta data analysis of more than 2,000 feed samples carried out annually, is the basis for Phileo by Lesaffre’s newly developed numerical platform. This platform combines existing company expertise in many fields, with the target of sharing findings with customers to help them develop their activities and address technical issues.

Published in association with Phileo by Lesaffre.